

[Original Paper]

Comparison of I-123 BMIPP, Tc-99m MIBI, and Tl-201 myocardial SPECT for prediction of late left ventricular function after reperfusion therapy for acute myocardial infarction

Koichi Sano, Shigeyuki Nishimura¹⁾, Kenichi Kato¹⁾,
Toshiko Ohta²⁾, Toshiharu Himi and Yoshiaki Masuda³⁾

(Received December 7, 2000, Accepted December 19, 2000)

SUMMARY

We prospectively evaluated I-123 beta-methyliodophenylpentadecanoic acid (BMIPP), Tc-99m methoxyisobutyl isonitrile (MIBI) and Tl-201 (Tl) SPECT images in 21 patients to determine which agent most accurately predicts late left ventricular function in patients with acute myocardial infarction (AMI). In all cases, the infarct-related artery was revascularized by primary PTCA. We performed SPECT with each of these three radionuclides at the subacute phase (1-3 weeks) of myocardial infarction. Polar map images were quantitatively compared to normal data from a data bank. Late left ventricular ejection fraction (EF) was calculated by contrast ventriculography at 4 months after the onset of myocardial infarction.

The mean defect sizes (>2 standard deviation below the mean count for normal data bank) by BMIPP, early Tl, delayed Tl and MIBI SPECT were 43%, 33%, 35% and 36%, respectively. There were good correlations between late EF and defect size by BMIPP ($r=0.77$, $p=0.0003$), early Tl ($r=0.69$, $p=0.002$), delayed Tl ($r=0.65$, $p=0.005$) and MIBI ($r=0.67$, $p=0.004$).

In conclusion, BMIPP imaging at the subacute phase of AMI is superior to rest Tl and MIBI imaging for prediction of late left ventricular function in AMI patients with successful reperfusion therapy.

Key words : I-123 BMIPP, Tc-99m MIBI, Tl-201, acute myocardial infarction

Abbreviations : BMIPP : beta-methyliodophenylpentadecanoic acid

MIBI : methoxyisobutyl isonitrile

SPECT : single photon emission computed tomography

AMI : acute myocardial infarction

EF : ejection fraction

IRA : infarct-related artery

Division of Cardiology, Kimitsu Central Hospital, Kisarazu 292-8535.

Division of ¹⁾Cardiology and ²⁾Radiology, Yokohama Rosai Hospital, Yokohama 222-0036.

³⁾3rd Department of Internal Medicine, School of Medicine, Chiba University, Chiba 260-8670.

佐野剛一, 西村重敬¹⁾, 加藤健一¹⁾, 太田淑子²⁾, 氷見寿治, 増田善昭³⁾ : 急性期再灌流療法を施行した急性心筋梗塞症例におけるI-123 BMIPP, Tc-99m MIBI, Tl-201 SPECT 定量所見と慢性期左心機能との対比

君津中央病院 循環器科, ¹⁾横浜労災病院 循環器科, ²⁾同・放射線科, ³⁾千葉大学医学部内科学第三講座
Tel. 0438-36-1071.

2000年12月7日受付, 2000年12月19日受理

I. Introduction

Left ventricular function after myocardial infarction is the strongest predictor of patient outcome[1]. Multiple randomized control trials have used left ventricular ejection fraction as a surrogate end-point of outcome in patients treated with thrombolytic therapy during acute myocardial infarction. However, several reports have demonstrated delayed improvement of left ventricular ejection fraction in patients receiving acute reperfusion therapy for myocardial infarction[2-6], and suggested that left ventricular ejection fraction before hospital discharge does not accurately reflect infarct size and is different from that in the chronic stable period because of the presence of stunned myocardium and compensating hyperkinetic movement of noninfarct area[2-9]. Several studies have therefore delayed the assessment of left ventricular function until the postdischarge period[10-12]. Thus, prediction of the truly recovered left ventricular function is important for risk stratification in patients with acute myocardial infarction.

Several studies for predicting late left ventricular function of acute myocardial infarction by the use of certain nuclear agents have been reported. The extent of Tc-99m MIBI defect at the subacute phase of myocardial infarction more closely correlates with the late left ventricular function rather than ventricular function at the subacute phase[9]. The defect size of BMIPP, a myocardial fatty acid imaging agent, more closely correlates with ejection fraction at the time of chronic phase than the defect size of Tl[13]. However, there has been no report concerning a comparison of I-123 BMIPP, Tc-99m MIBI and Tl-201 myocardial SPECT images. Therefore, to determine which agent most accurately predicts the late left

ventricular function in patients with acute myocardial infarction, we prospectively evaluated these three myocardial SPECT images at the subacute phase of myocardial infarction.

II. Materials and Methods

Patients

Twenty-one consecutive patients with first acute myocardial infarction admitted to Yokohama Rosai Hospital within 6 hours of the onset of symptoms were studied (Table 1). The patients were 17 men and 4 women with a mean age of 62 ± 11 ($\pm s$). The diagnosis of acute myocardial infarction was determined by the presence of persistent ST segment elevation of >2 mm in two or more leads on the electrocardiogram associated with precordial pain typical of acute myocardial infarction.

Selective coronary angiography was performed in all patients immediately after being admitted. The infarct-related artery was the left anterior descending artery in 15 (71%) cases, the right coronary artery in 4 cases (19%), and the circumflex artery in 2 cases (10%). All patients underwent emergent angioplasty and then all infarct-related arteries were confirmed by TIMI 3 flow.

Table 1. Clinical parameters of the study patients

Age (yr)	62 \pm 11
Sex (male)	17 (81%)
IRA	
LAD	15 (71%)
RCA	4 (19%)
LCX	2 (10%)

IRA, infarct-related artery; LAD, left anterior descending; RCA, right; LCX, left circumflex.

Radionuclide studies

Rest I-123 BMIPP, Tl-201, and Tc-99m MIBI

SPECT images were separately taken in randomized order at the subacute phase of myocardial infarction. I-123 BMIPP SPECT images were obtained 20 min after injection of 111 MBq of the agent. Tl-201 SPECT images were obtained 5 min (early image) and 4 hr (delayed image) after injection of 111 MBq of the radionuclide. Tc-99m MIBI SPECT images were obtained 1 hr after injection of 600 MBq of the agent.

All images were obtained on a triple-head rotating gamma camera equipped with a low energy, high resolution collimator (Toshiba GCA- 9300A). Sixty frames were obtained at 60 sec/view interval over a 360 arc. Energy discrimination was provided by a 20% window centered on 80 keV for Tl-201, 159 keV for I-123 BMIPP and 140 keV for Tc-99m MIBI. A series of transaxial images of 6 mm thickness were reconstructed by back projection technique without attenuation correction. Polar map images were generated for 20 radii by identifying the peak counts in every 10° sector around the left ventricle. Polar map images were quantitatively compared to normal data of a data bank separately generated for each test. The area showing $>2s$ below the mean count of the normal data was defined as hypoperfused area, and the percentage of hypoperfused left ventricle was calculated as % defect.

Follow-up study

Follow-up coronary angiography and contrast left ventriculography (RAO 30°) were performed at 3 weeks after onset ($n=17$) and 4 months after onset ($n=16$). At 4 months, coronary angiography showed restenosis of infarct-related artery in 5 patients (32%), and reocclusion in none. Ejection fraction was calculated by the area length method.

Statistical analysis

Data are presented as mean values \pm s. Simple linear regression analysis was used to compare % defect by I-123 BMIPP, Tl-201 and Tc-99m MIBI images with ejection fraction. A paired t test was used to compare ejection fraction at 3 weeks and 4 months after onset. One-way factorial ANOVA and multiple comparison test were used to compare % defect by I-123 BMIPP, early Tl-201, delayed Tl-201 and Tc-99m MIBI images.

III. Results

Left ventricular function

Left ventriculography was performed in 17 patients at 3 weeks of the disease after onset (mean 23 ± 7 days), and 16 patients at 4 months of the disease after onset (mean 117 ± 16 days). Ejection fraction (EF) at 3 weeks after onset was $52 \pm 14\%$, and that at 4 months was $58 \pm 13\%$. Fifteen of the patients underwent left ventriculography two times. In these 15 patients, there was a significant increase in EF from 3 weeks after onset to 4 months (Fig. 1).




Fig. 1 Ejection fraction (EF) at 3 weeks after onset and that at 4 months. Fifteen of the patients underwent left ventriculography two times. In these 15 patients, there was a significant increase in EF from 3 weeks after onset to 4 months.

Radionuclide parameters

Rest I-123 BMIPP, rest Tl-201, and rest Tc-99m MIBI SPECT were performed at 14 ± 4 days, 12 ± 4 days, and 20 ± 8 days after onset, respectively. The % defect by I-123 BMIPP was $43 \pm 17\%$, that by early Tl-201 $33 \pm 21\%$, that by delayed Tl-201 $35 \pm 13\%$, and that by Tc-99m MIBI $36 \pm 17\%$. The %




Fig. 2 Rest I-123 BMIPP, rest Tl-201, and rest Tc-99m MIBI SPECT were performed at 14 ± 4 days, 12 ± 4 days, and 20 ± 8 days after onset. The % defect by I-123 BMIPP was larger than those by the other agents, but there was no statistical significance between any of the differences.

defect by I-123 BMIPP was larger than those by the other agents, but there was no statistical significance between any of the differences (Fig. 2).

Correlation of radionuclide studies

Correlation coefficients between % defect by the respective radionuclide studies and EF at 3 weeks and 4 months after onset are shown in Table 2. The % defect by each radionuclide was more closely correlated with

Table 2.

	3weeks	4months
BMIPP	-0.59 ($p=0.01$)	-0.77 ($p=0.0003$)
early TI	-0.38 ($p=0.13$)	-0.69 ($p=0.002$)
delayed TI	-0.47 ($p=0.06$)	-0.65 ($p=0.005$)
MIBI	-0.46 ($p=0.06$)	-0.67 ($p=0.004$)

Correlation coefficients between % defect by the respective radionuclide studies and EF at 3 weeks and 4 months after onset. The % defect by each radionuclide was more closely correlated with EF at 4 months than at 3 weeks after onset. The best correlation coefficient was found between % defect by I-123 BMIPP and EF at 4 months after onset ($r=-0.77$).




Fig. 3 Comparison of % defect by each radionuclide studies and ejection fraction at 3 weeks after onset.




Fig. 4 Comparison of % defect by each radionuclide studies and ejection fraction at 4 months after onset. The best correlation coefficient was found between % defect by I-123 BMIPP and EF at 4 months after onset ($r = -0.77$).

EF at 4 months than at 3 weeks after onset. The best correlation coefficient was found between % defect by I-123 BMIPP and EF at 4 months after onset ($r = -0.77$) (Fig. 3, 4).

IV. Discussion

The accurate prediction of left ventricular function recovery is clinically important. The % defect by I-123 BMIPP, Tl-201 and Tc-99m MIBI studies at the subacute phase of myocardial infarction was more closely correlated with EF at the chronic phase than at the subacute phase, although 5 patients (24%) had a significant increase ($\geq 8\%$) in EF at 4 months compared with that at 3 weeks. Christian et al have already reported that the defect size of Tc-99m MIBI in acute myocardial infarction patients at the time of discharge more accurately reflects EF at the chronic phase rather than that at discharge[9]. This finding suggests that the defect size of these radionuclide studies may not be affected by the presence of stunned

myocardium and hyperkinesia of noninfarct area even if the study is performed at the subacute phase of myocardial infarction. This is an advantage of the nuclear method compared to the echocardiographic assessment at rest.

The metabolic approach may be theoretically superior to the flow approach because metabolic activity in the myocardium is more directly associated with wall motion (metabolic-contraction coupling). I-123 BMIPP was developed for fatty acid metabolic imaging with SPECT. In animal studies, myocardial uptake of I-123 BMIPP has been shown to reflect the myocardial intracellular ATP concentration, triglyceride content, and mitochondrial function[14-17]. In clinical studies, I-123 BMIPP findings were more closely correlated with ventricular function in the acute phase of myocardial infarction than Tl-201 findings[18,19], and the extent of I-123 BMIPP defect at the subacute phase in myocardial infarction patients was more strongly correlated with EF than that of Tl-201[13].

By defining hypoperfusion as $<2s$ compared with the normal data of a data bank, we measured the extent of hypoperfusion but not its severity. The influence of the severity of the perfusion defect needs to be assessed. However, in animal studies[20], the extent of hypoperfusion has been shown to accurately distinguish infarcted from noninfarcted myocardium.

This is the first report to show the direct and quantitative comparison among I-123 BMIPP, Tl-201 and Tc-99m MIBI in acute myocardial infarction patients with successful reperfusion therapy, and to examine which agent can most accurately predict late left ventricular function. The value of the % defect by I-123 BMIPP was the largest among of them. Our results were similar to those of previous studies[18,19,21]. Further, the % defect by I-123 BMIPP was most strongly correlated with EF at the chronic phase compared with those by early Tl-201, delayed Tl-201 and Tc-99m MIBI. A possible explanation for this difference is that I-123 BMIPP is more sensitive to ischemia than the other agents. Additional experimental studies will be needed to clarify the exact mechanism of this phenomenon.

Conclusion

The % defect by all radionuclide studies at the subacute phase of myocardial infarction was more closely correlated with ejection fraction at the chronic phase than that at the subacute phase. I-123 BMIPP imaging at the subacute phase of myocardial infarction is superior to rest Tl-201 and Tc-99m MIBI imaging for prediction of late left ventricular function in acute myocardial infarction patients with successful reperfusion therapy.

要 旨

心筋梗塞患者における慢性期左心機能の評価は予後を検討する上で重要である。今回再灌流療法を施行した急性心筋梗塞患者において、亜急性期に施行したI-123 BMIPP, Tl-201, Tc-99m MIBI SPECT 検査のうちどの核種が最も慢性期左心機能の予測に有用かを定量的に検討した。

急性心筋梗塞21例（平均62才）に対し亜急性期（平均15病日）に順不同にI-123 BMIPP, Tl-201, Tc-99m MIBI SPECT 検査を施行し各 polar map を作製した。各 polar map をそれぞれの normal data bank と比較し、 $-2s$ 以下を示した領域を hypoperfused area として % defect を算出、心筋梗塞発症4ヵ月後の左室造影より得られた駆出率と比較した。

I-123 BMIPP の初期像, Tl-201 の初期像, 後期像, Tc-99m MIBI の初期像の % defect はそれぞれ $43 \pm 17\%$, $33 \pm 21\%$, $35 \pm 13\%$, $36 \pm 17\%$ であった。心筋梗塞発症4ヵ月後の駆出率との相関は、I-123 BMIPP 初期像が最も強く（相関係数 $r = -0.77$, $p = 0.0003$ ）、次いで Tl-201 早期像（ $r = -0.69$, $p = 0.002$ ）、Tl-201 後期像（ $r = -0.65$, $p = 0.005$ ）、Tc-99m MIBI 早期像（ $r = -0.67$, $p = 0.004$ ）の順であった。


上記3種核種中、再灌流療法を施行した急性心筋梗塞症例において慢性期左心機能の予測にはI-123 BMIPP SPECT 検査が最も有用であった。

References

- 1) The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. *N Engl J Med* 1983; 309: 331-6.
- 2) Reduto LA, Freund GC, Gaeta JM, Smalling RW, Lewis B, Gould KL. Coronary artery reperfusion in acute myocardial infarction: beneficial effects of intracoronary streptokinase on left ventricular salvage and performance. *Am Heart J* 1981; 102: 1168-77.
- 3) Stack RS, Phillips HR 3rd, Grierson DS, Behar VS, Kong Y, Peter RH, Swain JL, Greenfield JC Jr. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. *J Clin Invest* 1983; 72: 84-95.
- 4) Topol EJ, Weiss JL, Brinker JA, Brin KP, Gottlieb SO, Becker LC, Bulkley BH, Chandra N, Flaherty JT, Gerstenblith G,

- Gottlieb SH, Guerci AD, Ouyang P, Llewellyn MP, Weisfeldt ML, Shapiro EP. Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplasty. *J Am Coll Cardiol* 1985; 6: 426-33.
- 5) Satler LF, Kent KM, Fox LM, Goldstein HA, Green CE, Rogers WJ, Pallas RS, Del Negro AA, Pearle DL, Rackley CE. The assessment of contractile reserve after thrombolytic therapy for acute myocardial infarction. *Am Heart J* 1986; 111: 821-5.
- 6) Grines CL, O'Neil WW, Anselmo EG, Juni JE, Topol EJ. Comparison of left ventricular function and contractile reserve after successful recanalization by thrombolysis versus rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1988; 62: 352-7.
- 7) Sheehan FH, Mathey DG, Schofer J, Krebber HJ, Dodge HT. Effect of interventions in salvaging left ventricular function in acute myocardial infarction: a study of intracoronary streptokinase. *Am J Cardiol* 1983; 52: 431-8.
- 8) Rogers WJ, Hood WP Jr, Mantle JA, Baxley WA, Kirklin JK, Zorn GL, Nath HP. Return of left ventricular function after reperfusion in patients with myocardial infarction: importance of subtotal stenosis or intact collaterals. *Circulation* 1984; 69: 338-49.
- 9) Christian TF, Behrenbeck T, Pellikka PA, Huber KC, Chesebro JH, Gibbons RJ. Mismatch of left ventricular function and infarct size demonstrated by technetium-99m isonitrile imaging after reperfusion therapy for acute myocardial infarction: identification of myocardial stunning and hyperkinesia. *J Am Coll Cardiol* 1990; 16: 1632-8.
- 10) White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. *N Engl J Med* 1987; 317: 850-5.
- 11) O'Rourke M, Baron D, Keogh A, Kelly R, Nelson G, Barnes C, Raftos J, Graham K, Hillman K, Newman H, Healey J, Woolridge J, Rivers J, White H, Whitlock R, Norris R. Limitation of myocardial infarction by infusion of recombinant tissue-type plasminogen activator. *Circulation* 1988; 77: 1311-5.
- 12) Ritchie JL, Cerqueria M, Maynard C, Davis K, Kennedy JW. Ventricular function and infarct size: the Western Washington intravenous streptokinase in myocardial infarction trial. *J Am Coll Cardiol* 1988; 11: 689-97.
- 13) Nishimura T, Nishimura S, Kajiya T, Sugihara H, Kitahara K, Imai K, Muramatsu T, Takahashi N, Yoshida H, Osada T, Terada K, Ito T, Naruse H, Iwabuchi M. Prediction of functional recovery and prognosis in patients with acute myocardial infarction by I-123 BMIPP and Tl-201 myocardial single photon emission computed tomography: A multicenter trial. *Ann Nucl Med* 1998; 12: 237-48.
- 14) Ogata M, Kajiya K, Yamaguchi Y, Koga Y, Toshima H. BMIPP uptake in adriamycin cardiomyopathic rat hearts. *J Mol Cell Cardiol* 1988; 20: 28-32.
- 15) Fujibayashi Y, Yonekura Y, Takemura Y, Wada K, Matsumoto K, Tamaki N, Yamamoto K, Konishi J, Yokoyama A. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S) methylpentadecanoic acid (BMIPP), in relation to ATP concentration. *J Nucl Med* 1990; 31: 1818-22.
- 16) Knapp FF Jr, Kropp J. Iodine-123-labelled fatty acids for myocardial single photon emission tomography: current status and future. *Eur J Nucl Med* 1995; 22: 361-81.
- 17) Yamamichi Y, Kusuoka H, Morishita K, Shirakami Y, Kurami M, Okano K, Itoh O, Nishimura T. Metabolism of iodine-123-BMIPP in perfused rat hearts. *J Nucl Med* 1995; 36: 1043-50.
- 18) Hashimoto A, Nakata T, Tsuchihashi K, Tanaka S, Fujimori K, Iimura O. Post ischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute

- myocardial infarction. Am J Cardiol 1996; 77: 25-30.
- 19) Ito T, Tanouchi J, Kato J, Morioka T, Nishino M, Iwai K, Tanahashi H, Yamada Y, Hori M, Kamada T. Recovery of impaired left ventricular function in patients with acute myocardial infarction is predicted by the discordance in defect size on I-123 BMIPP and Tl-201 SPECT images. Eur J Nucl Med 1996; 23: 917-23.
- 20) Verani MS, Jeroudi MO, Mahmarian JJ, Boyce TM, Borges-Neto S, Patel B, Bolli R. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m-hexakis-2-methoxyisobutyl isonitrile. J Am Coll Cardiol 1983; 1: 1047-55.
- 21) Nishimura T, Uehara T, Shimonagata T, Nagata S, Haze K. Clinical results with β -methyl-p-(123I) iodophenyl pentadecanoic acid, single photon emission computed tomography in cardiac disease. J Nucl Cardiol 1994; 1: S72-S78.



エーザイ株式会社
〒112-88 東京都文京区小石川4-6-10

資料請求先：医薬事業部セルベックス係
E-H9708

胃炎・胃潰瘍にセルベックス

胃炎：急性胃炎，慢性胃炎の急性増悪期

- 胃粘液分泌により胃粘膜の再生と保護作用を示す。
- 胃炎・胃潰瘍の欠損粘膜を修復し，治癒を促進する。
- 胃炎，特にびらんの内視鏡所見の改善にすぐれる。
- 副作用発現率は0.48% (52症例/10,914症例)。

主な副作用はGPTの上昇22件(0.20%)，GOTの上昇13件(0.12%)，発疹6件(0.06%)など(1991年2月)。

〔使用上の注意〕*

- (1)副作用*
(まれに：0.1%未満，ときに：0.1～5%未満，副詞なし：5%以上又は頻度不明)
- 1) 消化器／まれに便秘，腹部膨満感，下痢，口渇，嘔気，腹痛等があらわれることがある。
 - 2) 肝臓／ときにGOT，GPTが軽度上昇することがある。
 - 3) 精神神経系／まれに頭痛等があらわれることがある。
 - 4) 過敏症／まれに発疹，痒痒感等があらわれることがあるので，このような症状があらわれた場合には投与を中止すること。
 - 5) その他／まれに総コレステロールの上昇，眼瞼の発赤・熱感があらわれること

がある。

- (2)高齢者への投与
一般に高齢者では生理機能が低下しているため減量するなど注意すること。
- (3)妊婦への投与
妊娠中の投与に関する安全性は確立していないので，妊婦又は妊娠している可能性のある婦人には，治療上の有益性が危険性を上回ると判断される場合にのみ投与すること。
- (4)小児への投与
小児に対する安全性は確立していない(使用経験がない)。

* 1995年7月改訂

●ご使用に際しては，添付文書をご参照ください。

胃炎・胃潰瘍治療剤

(薬価基準収載)

セルベックス® カプセル 50mg/10%
(テブレンオン製剤)